Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Illumina Partner to Produce Exome Panel for Disease Research

NEW YORK – Twist Bioscience said on Tuesday that it has inked a partnership with Illumina to produce the co-branded Twist Bioscience for Illumina Exome 2.0 Plus panel for disease research.

Under the partnership, Twist will manufacture the Exome 2.0 Plus panel, which can be used on Illumina sequencers and will be sold by Illumina under the Illumina and Twist brands. According to Twist, the panel delivers the company’s "most up-to-date" set of protein-coding content as well as disease-associated and noncoding variants relevant to disease research. The kit’s "high uniformity and on-target rate as well as low dropout and duplicate read rates" allows Illumina users to achieve maximal coverage of target sequences with fewer wasted reads, Twist said.

Meanwhile, Illumina will offer the Exome 2.0 Plus panel with its DNA library preparation reagents as a kitted library prep and exome enrichment solution.

"By combining forces, we can offer best-in-class solutions to a broader range of customers, allowing more people to benefit from our detection capabilities," Twist CEO and Cofounder Emily Leproust said in a statement. 

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.